The research team, led by Pan Bian and colleagues at the First Affiliated Hospital of Henan University of Science and Technology, analyzed 142 adults admitted between January 2023 and December 2025 after stings documented from Vespa velutina, Vespa mandarinia, or Vespa basalis. Of 196 patients screened, 54 were excluded for incomplete records, prior severe anaphylaxis, immunosuppression, or age under 18. The remaining cohort was stratified at admission using a four-level institutional scheme: Grade I for local or minimal systemic reactions without organ dysfunction, Grade II for systemic allergic manifestations without organ dysfunction, Grade III for single-organ failure, and Grade IV for multi-organ failure or anaphylactic shock. The distribution was 42, 48, 34, and 18 patients across the four grades, with a median age of 52.4 years and 59.2 percent male.

The clinical gradients across severity groups were stark. Median sting count climbed from 11 in Grade I to 105 in Grade IV, and median time to hospital presentation lengthened from 1.4 to 2.8 hours. White blood cell count, C-reactive protein, liver enzymes, creatinine, and lactate dehydrogenase all rose progressively with severity, as did the Sequential Organ Failure Assessment score, which climbed from a median of 0 in Grade I to 11 in Grade IV. ICU admission rose from zero percent to 55.6 percent, in-hospital mortality from zero to 11.1 percent, and median hospital stay from 2 to 18 days. Demographics such as age and sex were similar across grades, underscoring that venom burden and presentation delay, not patient characteristics, tracked with outcome.

Archived serum stored at minus 80 degrees Celsius was available for 98 of the 142 patients, and the severity distribution among these patients closely matched that of the full cohort. The team measured four circulating proteins using ELISA-based assays: GSDMD-p30, the cleaved N-terminal fragment of gasdermin D; phosphorylated RIPK3 at residues Thr231/Ser232; and the inflammatory cytokines interleukin-1 beta and interleukin-18. All measurements were performed in duplicate with an inter-assay coefficient of variation below 10 percent, although the custom assays for GSDMD-p30 and p-RIPK3 were research reagents rather than clinically validated diagnostic tests.

The molecular signal mirrored the clinical one. Mean serum GSDMD-p30 increased from 0.82 nanograms per milliliter in Grade I to 9.43 nanograms per milliliter in Grade IV, while p-RIPK3 rose from 0.64 to 7.84 nanograms per milliliter, with global p values below 0.001 for both. Interleukin-1 beta climbed from 11.8 to 241.6 picograms per milliliter and interleukin-18 from 39.2 to 312.8 picograms per milliliter across the same severity span. All four proteins remained significant even under a conservative Bonferroni-adjusted threshold of 0.0125 applied to the prespecified comparisons.

Correlations with organ-failure burden were equally strong. Spearman rank coefficients against SOFA score reached 0.814 for GSDMD-p30, 0.791 for interleukin-18, 0.783 for p-RIPK3, and 0.762 for interleukin-1 beta, all with p values below 0.001. In exploratory same-cohort receiver operating characteristic analysis for Grade III-IV disease, apparent areas under the curve were 0.861 for GSDMD-p30, 0.843 for p-RIPK3, 0.834 for interleukin-18, 0.812 for interleukin-1 beta, and 0.807 for lactate dehydrogenase. The cell-death proteins modestly outperformed the conventional injury marker LDH in this discovery cohort, though the authors stress that no formal statistical comparison among the AUCs was performed.

The biology behind these markers is well characterized at the molecular level. Cleavage of gasdermin D by inflammatory caspases releases a pore-forming fragment that inserts into cell membranes, a defining event of pyroptosis, a lytic inflammatory cell-death program. RIPK3 phosphorylation is central to necroptosis, a parallel lytic pathway triggered by death-receptor signaling when caspase-8 activity is limited. Interleukin-1 beta and interleukin-18 are matured by the NLRP3 inflammasome, a multiprotein activation platform that itself promotes gasdermin D cleavage. PANoptosis, a proposed coordinated program integrating pyroptotic, apoptotic, and necroptotic machinery, provides a conceptual framework linking these pathways, but the authors are explicit that serum proteins cannot demonstrate PANoptosis, identify the cellular source of the markers, or show simultaneous execution of multiple death programs in the same cell.

The authors are equally careful about confounding. Sting burden and time to presentation differed materially across severity grades, and patients with larger venom exposure or delayed arrival may simultaneously have higher circulating injury and inflammation markers and worse outcomes. The biomarker-severity associations are therefore interpreted as unadjusted exploratory correlations rather than independent causal or prognostic effects. The four-grade severity scheme itself is institution-specific and has not undergone external validation, and archived serum was unavailable for 44 patients, leaving open the possibility of selection based on characteristics other than severity. The retrospective, single-center design further limits causal inference and generalizability.

The ROC estimates also demand restraint. They were obtained in the same 98-patient subset in which the biomarkers were studied, with only 35 Grade III-IV cases, and no independent validation cohort, train-test split, bootstrap optimism correction, or repeated cross-validation was available. The authors therefore report only apparent individual-marker discrimination and caution that these values should not be used for clinical decision-making without prospective validation. Complete analytical validation of the custom assays, including lower limits of detection, dynamic range, antibody specificity, freeze-thaw stability, and blinded inter-operator reproducibility, would also be required before clinical translation.

What the study does establish is a clinical association between circulating cell-death proteins and organ-dysfunction burden after Hymenoptera envenomation, consistent with established literature showing that toxic envenomation can produce acute kidney injury, hepatic injury, rhabdomyolysis, shock, and multi-organ dysfunction, particularly after multiple stings. The authors conclude that GSDMD-p30, p-RIPK3, interleukin-1 beta, and interleukin-18 may represent candidate severity-associated biomarkers, but that the present data do not establish PANoptosis, cell-specific origin, independent prognostic value, or a validated triage threshold. Prospective multicenter studies with standardized assay validation, complete covariate adjustment, and independent model validation are required before any of these proteins reaches the emergency department as a clinical tool.

Subject of Research: Circulating cell-death–associated biomarkers and inflammatory severity in Hymenoptera sting envenomation: a single-center retrospective study

Article Title: Circulating cell-death–associated biomarkers and inflammatory severity in Hymenoptera sting envenomation: a single-center retrospective study

Article References: Bian, P., Wang, Y., Zhang, S., Gui, Y., & Shen, Z. (2026). Circulating cell-death–associated biomarkers and inflammatory severity in Hymenoptera sting envenomation: a single-center retrospective study. Frontiers in Cell and Developmental Biology, 14, Article 1970146. https://doi.org/10.3389/fcell.2026.1970146

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1970146

Keywords: Circulating, cell-death, associated, biomarkers, inflammatory, severity, Hymenoptera, sting, envenomation, single-center, retrospective, scientific research